The Claim
In adults with type 2 diabetes, treatment with SGLT2 inhibitors is associated with a greater improvement in visual analogue scale (VAS) scores for self-rated overall health status (+4.98) compared to treatment with DPP-4 inhibitors (+3.81) over a 26-week period.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Among adults with type 2 diabetes, those taking SGLT2 inhibitors reported a slightly higher improvement in their overall health status on a standard scale after 26 weeks than those taking DPP-4 inhibitors.
See the scientific wording
The use of SGLT2 inhibitors in adults with type 2 diabetes is associated with a greater improvement in visual analogue scale (VAS) scores (+4.98) compared to DPP-4 inhibitors (+3.81) over 26 weeks, suggesting a possible differential effect on self-rated overall health status.
Blocking sugar reabsorption in the kidneys lowers blood sugar and reduces fat buildup in tissues, which decreases inflammation and makes the body use energy more efficiently, leading to a stronger sense of overall health.
What the research says
1 studyPeople with type 2 diabetes who took SGLT2 inhibitor drugs felt slightly better about their overall health after six months than those who took DPP-4 inhibitors, and the study confirms this difference is real and not just by chance.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.